Cohesin gene mutations in tumorigenesis: From discovery to clinical significance

57Citations
Citations of this article
150Readers
Mendeley users who have this article in their library.

Abstract

Cohesin is a multi-protein complex composed of four core subunits (SMC1A, SMC3, RAD21, and either STAG1 or STAG2) that is responsible for the cohesion of sister chromatids following DNA replication until its cleavage during mitosis thereby enabling faithful segregation of sister chromatids into two daughter cells. Recent cancer genomics analyses have discovered a high frequency of somatic mutations in the genes encoding the core cohesin subunits as well as cohesin regulatory factors (e.g. NIPBL, PDS5B, ESPL1) in a select subset of human tumors including glioblastoma, Ewing sarcoma, urothelial carcinoma, acute myeloid leukemia, and acute megakaryoblastic leukemia. Herein we review these studies including discussion of the functional significance of cohesin inactivation in tumorigenesis and potential therapeutic mechanisms to selectively target cancers harboring cohesin mutations. © 2014 by the The Korean Society for Biochemistry and Molecular Biology.

Cite

CITATION STYLE

APA

Solomon, D. A., Kim, J. S., & Waldman, T. (2014). Cohesin gene mutations in tumorigenesis: From discovery to clinical significance. BMB Reports. The Biochemical Society of the Republic of Korea. https://doi.org/10.5483/BMBRep.2014.47.6.092

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free